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Abstract
Literature surveys, taxonomical differences, and bioassay results have been utilized in the
discovery of new natural products to aid in Actinomycetes isolate-selection. However, no or
less investigation have been done on establishing the differences in metabolomic profiles of
the isolated microorganisms. The study aims to utilise bioassay- and metabolomics-guided
tools that included dereplication study and multivariate analysis of the NMR and mass spec-
tral data of microbial extracts to assist the selection of isolates for scaling-up the production
of antimicrobial natural products. A total of 58 actinomycetes were isolated from different
soil samples collected from Ihnasia City, Egypt and screened for their antimicrobial activities
against indicator strains that included Bacillus subtilis, Escherichia coli, methicillin-resistant
Staphylococcus aureus and Candida albicans. A number of 25 isolates were found to be
active against B. subtilis and/or to at least one of the tested indicator strains. Principal com-
ponent analyses showed chemical uniqueness for four outlying bioactive actinomycetes
extracts. In addition, Orthogonal Projections to Latent Structures Discriminant Analysis
(OPLS-DA) and dereplication study led us to further select two outlying anti-MRSA active
isolates MS.REE.13 and 22 for scale-up work. MS.REE.13 and 22 exhibited zones of inhibi-
tion at 19 and 13 mm against MRSA, respectively. A metabolomics-guided approach pro-
vided the steer to target the bioactive metabolites (P<0.01) present in a crude extract or
fraction even at nanogram levels but it was a challenge that such low-yielding bioactive natu-
ral products would be feasible to isolate. Validated to occur only on the active side of OPLS-
DA loadings plot, the isolated compounds exhibited medium to weak antibiotic activity with
MIC values between 250 and 800 μM. Two new compounds, P_24306 (C10H13N2) and
N_12799 (C18H32O3) with MICs of 795 and 432 μM, were afforded from the scale-up of MS.
REE. 13 and 22, respectively.
PLOS ONE | https://doi.org/10.1371/journal.pone.0226959 December 30, 2019 1 / 29
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Sebak M, Saafan AE, AbdelGhani S,
Bakeer W, El-Gendy AO, Espriu LC, et al. (2019)
Bioassay- and metabolomics-guided screening of
bioactive soil actinomycetes from the ancient city
of Ihnasia, Egypt. PLoS ONE 14(12): e0226959.
https://doi.org/10.1371/journal.pone.0226959
Editor: Kalimuthusamy Natarajaseenivasan,
Bharathidasan University, INDIA
Received: June 21, 2019
Accepted: December 10, 2019
Published: December 30, 2019
Copyright: © 2019 Sebak et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: MS was financially sponsored by the
Missions Sector, Ministry of Higher Education of
Egypt, https://www.mohe-casm.edu.eg/index.jsp.
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript. The fund was only
covering MS’s living expenses and research fees
during two years of study at Strathclyde Institute of
Introduction
Natural products research has played a vital role in drug discovery and development during
the last decades [1]. However, after spans of research and screening of microbial isolates for
their natural products production, the chance for discovery of new natural products from
microbial origin has declined over the years. Meanwhile, antimicrobial resistance of pathogens
is increasingly becoming very severe. Therefore, the urgent need for new antimicrobial agents
has augmented the interest of scientists to discover new antibiotics from natural sources [2].
About 45% of the 22,000 reported microbial natural products are produced by actinomy-
cetes, 38% are fungal metabolites and only 17% are from unicellular bacteria [3, 4]. Actinomy-
cetes have been known as a rich source of diverse secondary metabolites with various
biological activities [5]. Species of the genus Streptomyces have been described to produce
about 75% of the reported metabolites from actinomycetes [6, 7]. These secondary metabolites
are mainly biosynthesized by either polyketide or non-ribosomal peptide synthetases [8]. Acti-
nomycetes belong to the phylum Actinobacteria, characterized by fungal morphology and are
filamentous Gram-positive bacteria with high GC (guanine-cytosine) content. Actinomycetes
are distributed in many ecosystems including soil where they play an essential role in recycling
industrial wastes [8]. Egyptian soils have not been vastly investigated for their actinobacterial
reservoir and only few reports have been published on actinobacteria isolated from this ecosys-
tem [9–11].
Conventionally, the process of isolate selection and prioritization for further chemical isola-
tion work depended on either literature surveys, bioactivity screening, or phylogenetic analysis
of the isolates [12]. However, the strains of the same genus of bacteria which appear morpho-
logically identical may produce diverse chemical profiles and hence, different biological activi-
ties [13, 14]. On the other hand, isolates with vast differences in both their morphology and
phylogeny may have a similar metabolome [15]. An excellent strategy to reduce the chance of
isolating known compounds is by dereplication of secondary metabolites from each member
of the microbial collection prior to selecting the isolates for further chemical isolation work
[16]. Therefore, a new drug discovery strategy is using dereplication studies in parallel to mul-
tivariate data analysis [17–20]. Dereplication is briefly defined as the quick identification of
metabolites detected in a crude extract or fraction on the basis of a database of earlier reported
secondary metabolites [17, 21, 22].
Dereplication is considered a critical metabolomic tool used in isolate selection. Metabolo-
mics is a holistic analysis of the small compounds with molecular weight of less than 1000 Da
in a biological system at a specific time under a certain set of conditions [23]. LC-HRMS and
NMR based metabolomics is an efficient analytical tool to examine mixtures of compounds in
a biological system to aid in the discovery of new natural products [15, 24–26]. Statistical
approaches like unsupervised and supervised multivariate data analysis have been used to
check variation between different sample groups in terms of their chemical shifts in NMR and
m/z ratio in HRMS [27]. Metabolomic tools have been used to optimize the best fermentation
conditions for microbial isolates to yield their bioactive secondary metabolites [17, 21, 22] as
well as in the investigation and comparison between intra- and extra-cellular produced sec-
ondary metabolites [27, 28].
The main aim of the present study was to strengthen bioassay-guided tools by using a meta-
bolomics approach in prioritizing isolate selection from a collection of Egyptian soil Strepto-
myces while the concrete objective is to statistically define and pinpoint target novel bioactive
metabolites as well as known metabolites with new bioactivity directly from the crude bacterial
extracts prior to accomplishing a tedious chemical isolation and structure elucidation work
[17, 19]. In this paper, we would like to present a dereplication methodology utilizing
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multivariate analyses to compare and identify the interesting bioactive secondary metabolites
directly from crude extracts of bacterial isolates. As demonstrated by our earlier works on
other natural resources [29–37], such procedures will assist in optimizing the scale-up and
chromatographic isolation work on this yet underexplored collection of actinomycetes from
Egyptian soil isolates [9]. Anti-MRSA bioactivity was the targeted activity in this study, which
directed the prioritization of isolates for further chemical work. Although many previous stud-
ies on actinobacteria from Egypt have been published [38–44], most of these studies conducted
a bioassay-guided approach for screening the active isolates without any consideration for
chemical dereplication and thus, a metabolomics-based investigation is the core of our study.
Materials and methods
Samples collection and actinomycetes isolation
Several soil samples were collected between 2014 and 2016 from Ihnasia City located in Beni-
Suef Governate, Egypt. The ancient city of Ihnasia is located approximately 15 km west of the
modern city of Beni-Suef. Collection were done during the different seasons namely spring
when the weather is cooler and dry (March to May), summer that is hot and very dry (June to
August), and in autumn that is warm and a bit more humid (September to November) (S4
Table). No permits were required for site access to collect soil samples for academic research
work in Egyptian institutions for higher education. The soil samples were collected from a
depth of 15 to 20 cm of the superficial layers of the soil into sterile bags. Actinobacterial culti-
vation, isolation, and purification were done using a soil dilution plate technique [45] in Inter-
national Streptomyces Project 4 (ISP4) medium. ISP4 medium was supplemented with
rifampicin (10 μg/ml) to inhibit the growth of the fast-growing Gram-negative bacteria and
nystatin (50 μg/ml) to inhibit fungal growth and contamination. One gram of each soil sample
was diluted with 9 ml of 0.9% saline, then mixed, homogenized and prepared to ten-fold serial
dilutions up to 10−4. One ml from dilutions (10−2, 10−3 and 10−4) for each soil sample was
plated out on ISP4 agar plates using sterile cotton swabs, and the plates were incubated for 7 d
at 30˚C. Actinomycetes-like colonies depending on their morphological characters, pigment
diffusion, and coloration of their mycelia [46, 47] were picked and streaked several times on
ISP4 agar plates until pure actinobacterial colonies were isolated. The isolated actinomycetes
were maintained on agar plates for short-term storage and for long-term storage, the isolates
were archived by storing in 30% glycerol in ISP4 broth at -80˚C.
Antimicrobial activity screening
In vitro screening for antimicrobial activity of the actinobacterial extracts was done by cup dif-
fusion method against four different indicator strains [48]. The indicator strains used were B.
subtilis (ATCC 21228), Escherichia coli (E. coli) (ATCC 25922), MRSA (ATCC 43300) and
Candida albicans (ATCC 24433). Bacterial extracts were prepared by extraction of the extracel-
lular metabolites with ethyl acetate from 500 ml of initial broth cultures of ISP4 previously
seeded with 5% bacterial inoculum in Tryptone soya broth (TSB) and incubated at 30˚C for 7
d on a rotary shaker incubator at 160 rpm. Briefly, after surface inoculation of the tryptone
soya agar plates with 100 μl of the standard strains, a sterile borer was used to form 4 cups in
each plate with a diameter of 10 mm, then 150 μl of each extract solution (1 mg/ml) was added
in the cups. Finally, after incubation of the plates for 24 h, the antimicrobial activities were
assessed from the inhibition zones around the cups. Streptomycin solution in concentration of
1 mg/ml was used as the reference standard or positive control.
Screening of bioactive natural products from soil actinomycetes
PLOS ONE | https://doi.org/10.1371/journal.pone.0226959 December 30, 2019 3 / 29
Bacterial fermentation and extraction
All bioactive isolates were selected for further metabolomic profiling studies. Fermentation of
the selected bioactive isolates was done by sub-culturing them in TSB and incubated at 30˚C
for 3 d. Twenty-five milliliters of the TSB (5% inoculum) was used to inoculate 500 ml of ISP4
broth in 1 L flask and then incubated at 30˚C for 7 d on rotary shaker incubator at 180 rpm.
Culture growth was terminated with 1:1 v/v HPLC grade ethyl acetate and left for 24 h, then fil-
tered using a Buchner funnel with 100 mm filter papers. The filtrate was then transferred to a 1
L separating funnel and liquid–liquid partitioning was accomplished between water and ethyl
acetate. The aqueous filtrate was partitioned three times with equal volumes of ethyl acetate to
extract all organic metabolites. Ethyl acetate fractions were concentrated under vacuo with a
rotary evaporator. The dried crude extract was weighed and reconstituted with the appropriate
solvent for chemical analysis and bioassay screening [49, 50].
The culture conditions and extraction procedures for the scale-up of the selected isolates
(MS.REE. 13 and MS.REE. 22) were the same as that of the small-scale fermentation of the bio-
active isolates using ISP4 broth as mentioned above. In the present study, ISP4 broth was
seeded by 5% tryptone soya broth which contains pancreatic digest of casein, dextrose and
enzymatic digest of soya bean.
Mass spectrometry
Aliquots of crude bacterial extracts along with medium (ISP4) control samples were prepared
at 1 mg/ml solutions in methanol. Methanol solvent blank was also included in the analysis.
LC-HRMS of the samples was run on an Accela HPLC (Thermo Scientific, Germany) coupled
to an Exactive mass spectrometer (Orbitrap, Germany) with an electrospray ionization source
according to [31]. Briefly, mass accuracy of the mass detector was set to less than 3.0 ppm. The
instrument was calibrated internally using lock masses and externally according to the instruc-
tions of the manufacturers. High resolution mass spectrometry was carried out over a mass
range of 150–1500 m/z in both negative and positive ionization switch modes. The instrument
capillary temperature was set at 270˚C with a spray voltage of 4.5 kV. The LC-HRMS experi-
ments were carried out with ACE5 Excel 3 Super C18 column (5 μm × 150 mm × 3 mm)
(Hichrom Limited, Reading, UK), using 10 μl as injection volume from each vial. The two
mobile phases used to carry out the mass spectrometry were ultrapure water with 0.1% formic
acid (Solvent A) and HPLC grade acetonitrile with 0.1% formic acid (Solvent B). The gradient
started with 10% solvent B at a flow rate of 0.3 ml/min and the percentage of solvent B was lin-
early increasing to 100% within 30 minutes. Then remained isocratic at 100% B for 5 minutes
before decreasing again within one minute to 10% B which continued isocratic at 10% B as
final washing for 10 minutes before the next sample injection. The sample tray and the column
oven temperatures were maintained at 4˚C and 20˚C respectively. The run sequence started
with the blank solvent then the blank medium followed by the samples. The HRMS data of the
blanks and the samples were acquired using Xcalibur software version 3.
NMR spectroscopy
For NMR study, NMR samples for both culture medium and bacterial extracts were prepared
by dissolving 5 mg of the crude organic extracts of the medium and bacterial isolates in 600 μl
DMSO-d6 then transferred to 5 mm 7@ NMR tubes [19]. Correlation Spectroscopy (COSY)
and proton NMR was carried out on a 400 MHz Jeol-LA400 FT-NMR spectrometer system
equipped with a 40TH5AT/FG probe. For both COSY and proton NMR experiments, 16 scans
were recorded. Proton and COSY spectra were processed using MestReNova (Mnova 10.00,
Mestrelab Research SL, US) software. For Proton Spectra, smoothing with Whittaker
Screening of bioactive natural products from soil actinomycetes
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Smoother, baseline correction with Whittaker Smoother, apodization with Gaussian 1.00 and
manual phase correction were carried out in MestReNova (Mnova 10.00). For COSY analysis,
smoothing with Whittaker Smoother, reducing t1 noise and symmetrizing as COSY-like were
done, then spectra from the bacterial extracts were overlaid with the ISP4 medium spectrum
(control) to differentiate correlations from metabolites produced by the bacteria from those
coming from the culture medium.
Metabolomic profiling analysis of the LC-HRMS and NMR data
Using MassConvert tool from Proteowizard, the raw HRMS data were split into two different
data sets (positive mode data set and negative mode data set) [51]. The split data set in the for-
mat of mzML was imported into MZmine 2.20 [52] to extract features from the raw data. Data
processing was carried out for the individual data sets using MZmine 2.20 following a multi-
step protocol [31], commencing with peak detection (mass detection and chromatographic
builder) followed by deconvolution, deisotoping, filtering, alignment and gap filling. Finally,
adducts and complexes were identified while respective ion peaks were eliminated to minimize
the mis-assignment of features and to predict molecular formulae using an accuracy of 5 ppm
for each feature were carried out.
The generated CSV files for positive and negative modes by Mzmine 2.20, were copied into
an in-house Excel macro for further data clean-up [19]. Briefly, an in-house Excel macro was
used to subtract background ion peaks found in the solvent blank and medium, then simulta-
neously both negative and positive ionization modes data files generated by MZmine were
combined in preparation for multivariate data analysis and finally to dereplicate the metabo-
lites in the samples with those in the Dictionary of Natural Products (DNP) database. All peaks
of the solvent blank, which had peak intensity greater than 1 × 104 were subtracted manually
from the samples’ peaks. Peaks originating from the ISP4 medium were also subtracted from
the samples by applying an algorithm, which calculates each m/z intensity in both medium
and bacterial extracts. All ion peaks coming from the medium were subtracted leaving only
those features with peak intensity 20 times greater in the samples than in the ISP4 medium.
The data sets of both negative and positive ionization modes data sets were combined by
macro after removing the effect of the medium enabling ion peaks that were observed in both
modes and one of them to be overlaid for further statistical analysis. Finally, an Excel macro
was used for dereplication of each m/z ion peak with metabolites in the customized database
(DNP). This database provided us with the details on the already known compounds in the
bacterial extracts and the unknown hits which can help for targeting new bioactive metabolites
in the extracts and help in selecting the promising isolates for further scale-up as well.
The SIMCA data sheet generated by the Excel macro was then exported to SIMCA 15.0.1
(Umetrics, Umeå, Sweden) to do the multivariate data analysis (MVA). The data set was ana-
lyzed using both PCA and Orthogonal Projections to Latent Structures Discriminant Analysis
(OPLS-DA), respectively an unsupervised and a supervised MVA method with Pareto scaling
[53]. PCA was used to compare the chemical profiles of the different samples without classify-
ing them while OPLS-DA was generated by comparing the chemical profiles by pre-grouping
the isolates according to their bioassay screening results against MRSA and E. coli. The meta-
bolomics profile tables of interesting bioactive metabolites were deduced from the S-plots of
the OPLS-DA by selecting the discriminating compounds found on the bioactive extracts and
comparing them to the dereplication data sheet generated by the Excel macro. Depending on
the results of the dereplication study, bioassay screening, and the multivariate data analysis of
the bioactive bacterial extracts, promising isolates were selected for further scale-up.
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For proton NMR spectra, the processed spectra of the medium and different extracts were
stacked using MestReNova software (Mnova 10.00) and using an advanced PCA tool of
Mnova 10.00, a spectral data set was generated for further data analysis. The data set between
0.5 to 12.5 ppm of the medium and extracts were copied to an Excel sheet and the peaks of the
solvent used (DMSO and water peaks) were deleted. Finally, the resulting peak list was
exported to SIMCA 15.0.1 for multivariate analysis (PCA and OPLS-DA).
Taxonomical identification of the selected isolates through molecular
biology
DNA of two selected isolates for the scale-up was extracted. A single colony of each isolate
from the agar plate was inoculated to 4 ml of ISP2 broth and incubated at 30˚C for 3 d. One
ml of the bacterial broth culture was centrifuged for 10 min at 3000 rpm to separate the
cells. The cells were suspended in 300 μl of Tris-EDTA buffer with 5 mg/ml lysozyme and
0.1 mg/ml RNase, vortexed and incubated at 37˚C for 30 min to confirm that the cells were
properly lysed. Then, 50 μl of 10% SDS and 85 μl of 5 M NaCl were added and mixed thor-
oughly. To the suspended lysed cells, 400 μL of phenol: chloroform: isoamyl alcohol
(25:24:1) were added, vortexed for 30 s and centrifuged at 13200 rpm and the top aqueous
phase was transferred to a new tube. A 400 μl solution of chloroform: isoamyl alcohol (24:1)
was added, vortexed for 30 s and centrifuged for 10 min at 13200 rpm and the aqueous layer
was transferred to new tube. A volume of 500 μl isopropanol was added to the aqueous
layer, mixed by inversion and let sit at room temperature for 5 min. Finally, spin down at
10000 rpm for 5 min to pellet the DNA, remove isopropanol very gently and wash out the
DNA with 1 ml cold 70% ethanol. The ethanol was gently removed. The final DNA pellet
was left to dry on bench for 1 h and then resuspended in 50 μl sterile H2O and kept in the
fridge at 4˚C for further work.
For taxonomical identification of the selected isolates through molecular biology, 16S rRNA
genes of both isolates were amplified by PCR using a universal 27F primer (5`-AGAGTTTGAT
CMTGGCTCAG-3`) and universal 1492R primer (5`-GGTTACCTTGTTACGACTT-3`) [54].
The PCR amplification was carried out in total volume of 25 μl reaction mixture which con-
sisted of 1 μl genomic DNA, 0.25 μl of each primer, 0.2 μl MyTaq DNA polymerase (Bioline),
5 μl of 5x reaction buffer (New England Biolabs) to which dNTPs were added and finally sterile
water was added to make the total reaction volume 25 μl. The PCR was carried out according to
the following thermal protocol: initial denaturation for 5 min at 95˚C, followed by 29 cycles
starting with denaturation at 95˚C for 10 s, then annealing at 55˚C for 30 s and extension for 3
min at 72˚C with final extension after finishing the cycles at 72˚C for 4 min. Agarose gel electro-
phoresis was used to check the PCR amplification by loading 5 μl of each PCR product in 1%
(w/v) agarose at 100 V for 60 min and compared with 1 Kb ladder (Promega) as reference using
GelRed for staining (Biotium). Then, the PCR products were purified using ISOLATE II PCR
and Gel Kit (Bioline) following the manufacturer’s protocol for PCR products purification.
Finally, a concentration of 10 ng/μl for each purified PCR product was prepared and sent to
GATC (Germany) for sequencing using the 27F and 1492 R primers.
Good quality sequences were selected and compared to the GenBank database using the
Megablast tool of National Center for Biotechnology Information (NCBI) to optimize con-
trasting the amplified sequences against only the highly similar sequences in the GenBank
database to identify the closest related strains to our amplified sequences [55]. Multiple
sequence alignment and phylogenetic analysis of the isolates sequences were carried out using
MEGA7 software [56].
Screening of bioactive natural products from soil actinomycetes
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Results and discussion
Actinomycetes isolation and antimicrobial activity screening
A total of 58 bacterial strains were isolated and purified from soil samples from Egypt by sev-
eral successive and repetitive inoculation. Many previous reports confirmed the richness of
soil niches with important actinomycete isolates [57, 58]. Isolates were characterized as actino-
mycetes depending on their morphological characters, pigment diffusion, and coloration of
their mycelia.
ISP4 broth was the chosen culture media as it exhibited consistency in the antimicrobial
activity for all bioactive strains, which as well indicated stability of the type of bioactive metab-
olites between cultivation and scale-up during the present study. As mentioned in a previous
report, polysaccharides like starch as carbon source present in ISP4 is commonly used for opti-
mum production of antibiotics due to supporting slower microbial, growth which is suitable
for antibiotics biosynthesis [59]. Also, as shown in many previous studies in the literature, the
use of ISP4 in both isolation and fermentation work has yielded good results [9, 60–63]. ISP4
was the best culture medium for isolating actinomycetes when compared to other media such
as ISP2, ISP3, actinomycete isolation agar, glucose asparagine agar and starch-yeast extract
agar [60]. ISP4 as a culture medium also exhibited suitable production of antimicrobial agents
by Streptomyces in agar plates. Extracellular metabolomic screening of fermentation cultures
of different Streptomyces isolates in modified ISP broth medium (with added 0.4% yeast
extract) yielded various analogues of pyrromycin, erythromycin, doxorubicinol, and some
other putative novel metabolites indicating that ISP4 broth was most appropriate for the pro-
duction of various classes of antibiotics [61]. Interestingly, another earlier study showed that
ISP4 broth with 2.5% starch instead of 1% was the best media for production of antibiotics by
a Streptomyces strain isolated from soil samples collected from Egypt as well [62], as ISP4
broth was compared to other culture media such as ISP2 broth, tryptone-yeast extract-glucose
broth, starch-nitrate broth medium in this particular study. More recently, ISP4 was also used
to culture Streptomyces strains collected from Egyptian soil isolates for producing various clas-
ses of bioactive compounds both as antibacterial and anticancer agents [9]. ISP4 broth was
also used for the discovery and overproduction of the nucleoside antibiotic A201A from
marine-derived actinomycete Marinactinospora thermotolerans [63].
Extracts of collected bacterial isolates were initially screened against B. subtilis in various
solvents using hexane, chloroform, dichloromethane and ethyl acetate by cup diffusion
method [48] (S1 Fig). Hexane and chloroform extracts did not exhibit any antimicrobial activ-
ity in comparison to ethyl acetate and dichloromethane. A second screening for antimicrobial
activity against four indicator strains (B. subtilis, E. coli, MRSA and C. albicans) was repeated
with ethyl acetate extracts of the bacterial isolates. Ethyl acetate was the chosen extracting sol-
vent because it was able to isolate most of the bioactive semi-polar components while efficient
partitioning of inactive long alkyl chains and sugar molecules could be accomplished. Ethyl
acetate was also considered to be less expensive and less toxic to handle than dichloromethane.
Positive inhibition of at least one of the tested indicator strains was exhibited by 25 extracts
(43% of the collected isolates) as shown in Table 1. A clear zone of inhibition of greater than 12
mm diameter was considered as active. In many previous reports, a high percentage of biologi-
cal activity has been exhibited by soil actinomycete isolates [9, 64, 65], which matches our anti-
microbial activity screening results. A broad spectrum of antibacterial activity against all the
tested bacteria (B. subtilis, E. coli and MRSA) was demonstrated by five isolates as earlier
reported for a collection of soil actinomycete isolates from Egypt [9].
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Data processing and clean-up
Metabolomic profiles of the bioactive crude extracts were investigated using NMR and
LC-HRMS according to the workflow chart shown in Fig 1. After processing the HRMS
data using MZmine 2.20 as described in the methodology section, data clean-up was done
by importing the CSV files of both positive and negative modes data to an Excel macro. The
Excel macro helped in overcoming the limitations of MZmine 2.20 by combining the data
of positive and negative modes, which is particularly important for metabolites ionizing on
both modes that enabled merging the features observed in either or both modes together.
Thus, this valuable Excel macro optimized the processing of each ion peak along with those
detected only in one mode. This is also essential for data analysis of compounds like pheno-
lics and anthraquinones, which ionize only in the negative mode and are poorly ionize in
the positive mode [22].
Another problem for data analysis of bacterial extracts is the presence of background peaks
from the culture media. Most of the constituents of the culture media should be utilized by the
bacterial isolates during the fermentation process. However, some of the media constituents
may remain unutilized while trace amounts can be detected by LC-HRMS. These interfering
peaks from the medium could be misleading during the dereplication study, so the medium
was instead considered as one of the blank samples. Then, medium interfering peaks were
removed using the in-house Excel macro as mentioned in the methodology section.
Table 1. Antimicrobial activity of the actinomycetes isolates against different indicator strains used in the study. The zones of inhibition were measured and
recorded as active when it was greater than 12 mm. Twenty-five bioactive isolates were found and presented in this table out of the total 58 isolated actinomycetes.
Isolate Extract vs B. subtilis vs MRSA vs E. coli vs Candida albicans
MS.REE. 1 Active Active Inactive Inactive
MS.REE. 3 Active Inactive Active Inactive
MS.REE. 4 Active Active Inactive Inactive
MS.REE. 6 Active Inactive Active Inactive
MS.REE. 9 Active Inactive Inactive Inactive
MS.REE. 10 Active Active Active Inactive
MS.REE. 12 Active Inactive Inactive Inactive
MS.REE. 13 Active Active Active Inactive
MS.REE. 14 Active Inactive Active Inactive
MS.REE. 16 Active Inactive Active Inactive
MS.REE. 17 Active Inactive Inactive Inactive
MS.REE. 18 Active Inactive Inactive Inactive
MS.REE. 19 Active Inactive Active Inactive
MS.REE. 22 Active Active Active Inactive
MS.REE. 24 Active Inactive Inactive Inactive
MS.REE. 25 Active Active Active Inactive
MS.REE. 26 Active Active Active Inactive
MS.REE. 27 Active Active Inactive Inactive
MS.REE. 28 Active Active Inactive Inactive
MS.REE. 29 Active Inactive Active Inactive
MS.REE. 32 Active Inactive Inactive Inactive
MS.REE. 33 Active Inactive Inactive Inactive
MS.REE. 34 Active Inactive Inactive Inactive
MS.REE. 36 Active Inactive Active Inactive
MS.REE. 46 Active Inactive Inactive Inactive
https://doi.org/10.1371/journal.pone.0226959.t001
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Metabolomic profiling analysis for isolate prioritization
PCA analysis of the 25 extracts for three components gave R2 (goodness of fit) and Q2 (predict-
ability) values at 0.5 and 0.1, respectively, where 84% of the isolates clustered together. The
projected R2 and Q2 values are highly application dependent [53]. Biological PCA models are
expected to yield R2 and Q2 values of at least 0.5 and 0.4, respectively. In general, R2 should not
exceed Q2 by more than 2 units. The low predictability of the model was due to the low differ-
ence in chemical profiles of 84% of the analyzed samples, which consisted of 21 isolates. Iso-
lates MS.REE. 3, 6, and 13 were classified as outliers within the tolerance ellipse of 95%
hotelling at T2 as shown in the scores plot (Fig 2A). Outlying isolates indicated chemical
uniqueness as they lay far from the other isolates clustered in the center or within the eclipse.
Conversely, 84% of the isolates clustered with the media control except for MS.REE-22. How-
ever, this clustering of 84% of the isolates was not because of their low chemical diversity but
would be due to the relatively vast difference in profiles of these extracts when compared to the
outliers in terms of their yield and complexity. This was evident on the percentage variation
on PC1 and PC2 at 27.7 and 14.2, respectively before excluding the outliers, which was then
subsequently reduced to 18.3 and 10.1, respectively. The higher percentage variation in the
presence of the outliers merely implied that 84% of the isolates have a lower capability of
affording the same intensity of variation of secondary metabolites in comparison to the outli-
ers. Additionally, the chemical diversity of 84% of the tested isolates was validated by extract-
ing the PCA scores plot of the cluster from the four outlying extracts MS.REE. 3, 6, 12, and 22
(Fig 2B). As shown in Fig 2B, 67% of the extracts segregated from the medium with no clear
clustering, particularly those active samples against MRSA, indicating their distinct chemical
profiles although they were less diverse than the outliers. This further suggested that ISP4 was
indeed an appropriate standard media for this bioscreening campaign for this selection of
Actinomycetes. Outliers MS.REE. 3 and 6, which were only found active against E. coli and
Fig 1. Metabolomics workflow chart to aid isolates selection.
https://doi.org/10.1371/journal.pone.0226959.g001
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inactive against MRSA, were then excluded for further multivariate analysis (Fig 2C). In this
case, this was the first criteria to consider MS.REE.13 and 22 for scale-up work. MS.REE.13
exhibited zones of inhibition at 19 and 18 mm against MRSA and E. coli, respectively, MS.
REE.22 gave 13 and 18 mm, respectively. MS.REE. 3 and 6 yielded inhibition zones of 18 and
22 mm against E. coli, respectively. Streptomycin was used as positive control and displayed a
25 mm zone of inhibition against both MRSA and E. coli.
The loadings plot of the m/z ion peaks shown in Fig 2D indicated the metabolites of the iso-
lates, matching the same quadrant position of the isolates in the scores plot (Fig 2C). As shown
in the loadings plot (Fig 2D), the metabolites responsible for the separation of isolate MS.
REE.13 had lower molecular weights ranging from 200 to 400 Da, while MS.REE. 22 outlier
metabolites had higher molecular weights ranging from 300 to 500 Da. Both MS.REE. 13 and
22 showed promising activity against MRSA, E. coli and B. subtilis indicator strains (Table 1),
while MS.REE. 3 and 6 showed no activity against MRSA, which was the main target activity
for initial scale-up work.
The antimicrobial activity of the isolates was used to generate the supervised model
(OPLS-DA) by classifying the isolates according to their bioassay screening results against
MRSA and E. coli (Figs 3 and 4). The OPLS-DA model based on the bioactivity of the 23 iso-
lates against MRSA (Fig 3A) generated from 19 orthogonal X components for MRSA bioactiv-
ity gave an R2 value of 0.99 but with poor predictability Q2 value of 0.07. Percentage variation
between groups was 5.86% while within groups was 22.6%. The higher percentage variation
within groups can be explained by the separation of the outlying bioactive isolate MS.REE.13.
Fig 2. PCA of LC-HRMS data of 25 bacterial extracts tested against MRSA. (2A) Scores plot of the 25 extracts. (2B) Scores plot of 21 extracts after removal of
outlying samples MS.REE. 3, 6, 13, and 22. (2C) Scores plot after removal of the outlying inactive isolates MS.REE. 3 and 6. (2D) Corresponding loadings plot of ion
peaks in m/z highlighting the significant metabolites of the outlying bioactive isolates MS.REE. 13 and 22.
https://doi.org/10.1371/journal.pone.0226959.g002
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However, for visualization purposes, it was possible to define the bioactive target metabolites
responsible for separating MS.REE. 13 and 22 not only from the inactive isolates but as well as
from the rest of the bioactive isolates as shown on the OPLS-DA loadings plot (Fig 3B). The
active and inactive end of the S-plot matches the position of the respective groups as found on
the OPLS-DA scores plot is either positioned on the left or right quadrant of the ellipse. The
detected bioactive secondary metabolites were dereplicated and listed on Table 2. The loadings
S-plot shown on Fig 3C indicated the bioactive metabolites separating the active from those of
the inactive isolates against MRSA. The bioactive discriminating metabolites against MRSA
were listed on Table 2. Smaller P values� 0.10 indicated stronger evidence for predicted bioac-
tivity against MRSA, most of which were detected from isolates MS.REE. 13 and 22. The rela-
tive abundance of these discriminating active metabolites was shown on Fig 3D. These
included ion peaks at m/z 379.165 [M+H]+ and 566.245 [M-H]- with their predicted molecular
formulas C22H22N2O4 (ring-plus-double-bond equivalent (RDB) = 13) and C37H33N3O3
(RDB = 23), respectively.
For the MVA of the bioactivity of 25 extracts against E. coli, using two components, an R2
value of 0.79 was attained. Percentage variation between groups was 6.7% while within groups
(also known as internodal variation) was 23%. The separation of the outlying bioactive isolates
MS.REE.3 and 6 resulted to the higher percentage variation within groups (Fig 4A). As also
shown in Fig 4A, the OPLS-DA scores plot (Fig 4A) for the bioactivity of the isolates against E.
coli revealed the uniqueness of MS.REE. 3 and 6 with metabolites with molecular weights rang-
ing from 200 to 600 Da (Fig 4B). S-loadings plot was also generated for anti-E. coli bioactivity
(Fig 4C). The interesting bioactive secondary metabolites were detected mainly from isolates
Fig 3. OPLS-DA of LC-HRMS data of 23 extracts tested against MRSA after removal of the outlying inactive isolates MS.REE. 3 and 6.
(3A) Scores and (3B) loadings plot of ion peaks in m/z. (3C) Loadings S-plot against MRSA with predicted bioactive metabolites labelled with
their m/z ion peaks on the left lower quadrant. (3D) Column plot indicating the relative concentration in ion peak intensity of predicted
bioactive metabolites found in the bioactive isolates MS.REE. 13 and 22. The predicted bioactive metabolites are listed under their MZmine IDs
in Table 2 with their P values as determined from the S-plot.
https://doi.org/10.1371/journal.pone.0226959.g003
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MS.REE.3, 6, 13, and 22 as shown on Fig 4D designating their relative abundance, which will
be targeted to optimize their yield during the scale-up work.
Regarding the specificity of the discriminating bioactive metabolites against MRSA and E.
coli, unique metabolites can be assigned for the respective test strains, Table 2 (Fig 5A and 5B).
Metabolites anticipated to be specific against MRSA included P_15627, P_15328, P_11499,
and N_4053 at m/z 312.170 [M+H]+, 330.181 [M+H]+, 441.188 [M+H]+, and 566.450 [M-H]-,
respectively. On the other hand, N_2020, an ion peak at m/z 305.138 [M-H]- was predicted to
be specific against E. coli. Dereplication results are further presented and discussed below.
PCA of the proton NMR data of the 25 bioactive isolates achieved R2 and Q2 values of 0.84
and 0.59, respectively from 5 components. PCA-scores plot (Fig 6A) of the proton NMR data
showed a comparable result to the PCA results of the HRMS data exhibiting the chemical
uniqueness of isolates MS.REE. 3, 6, and 13, which were withdrawn from the rest of the isolates
establishing the main cluster. However, the clustering of the isolates was less dense in the cen-
ter of the ellipse when compared to the PCA plot of the HRMS data. Isolates on the right quad-
rant were more distant from the media, particularly MS.REE. 9, 14, 16, 19 and 22. MS.REE. 6
and 16 were indicated as outliers. On the scores plot of the HRMS data (Fig 2B), MS.REE. 16
was not an outlier but instead clustered together with the media. The chemical shifts causing
the significant separation of the outliers and the other isolates were indicated in the loadings
plot (Fig 6B). Isolates MS.REE. 3, 6, and 13 on the left upper quadrant were dominated by the
signals 2–5 ppm, which indicated acetylated and/or glycosidic metabolites. While on the right
quadrant represented by isolates MS.REE. 9, 14, 16, 19 and 22 were presided with chemical
shifts between 0 and 2 ppm directed towards the presence of saturated fatty acids in the
Fig 4. OPLS-DA of LC-HRMS data of 25 extracts tested against E. coli. (4A) Scores and (4B) loadings plot of ion peaks in m/z. (4C)
Loadings S-plot against E. coli with predicted bioactive metabolites labelled with their m/z ion peaks on the left lower quadrant. (4D)
Column plot indicating the relative concentration in ion peak intensity of predicted bioactive metabolites found in the bioactive isolates
MS.REE. 3, 6, 13, and 22. The predicted bioactive metabolites are listed under their MZmine IDs in Table 2 with their P values as
determined from the S-plot.
https://doi.org/10.1371/journal.pone.0226959.g004
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aforementioned isolates. Aromatic signals between 6 and 12 ppm were found on the center of
the ellipse where the media was also positioned.
Both the outlying isolates MS.REE. 6 and 16 did not exhibit any bioactivity against MRSA.
OPLS-DA plots (Fig 6C and 6D) of the bioactivity of isolates against MRSA, similarly, indi-
cated the chemical uniqueness of isolates MS.REE. 13 and 22 as determined from the multivar-
iate analysis of the HRMS data. MS.REE. 13 and 22 were situated at the end of the active
cluster on the left quadrant of the scores plot (Fig 6C), positioned at the upper and lower quad-
rants, respectively. The internodal variation score within the group was at 30.7% while the vari-
ation score between the groups was at 5.93% as the isolates for both groups were distributed
on both the upper and lower quadrants of the scores plot. The S-plot shown on Fig 6D
Table 2. Predicted discriminating metabolites found against MRSA and E. coli determined from their respective OPLS-DA S plots as shown in Figs 3 and 4. Ioniza-
tion mode is designated on MZmine ID as P for positive mode [M+H]+ and N for negative mode [M-H]-. Highlighted rows list the unique metabolites found for the
respective bioactivities. Smaller P values� 0.10 indicate stronger evidence for predicted bioactivity.
MZmine
ID
RT
(Min)
m/z MW
(accuracy
in ppm)
Formula
Prediction
/ RDB
Hits in DNP database
(compound no)
/ Source
Isolate no. w/
highest
intensity
P value MRSA
bioactivity
P value
E. coli
bioactivity
P_11499� 5.94 441.188 440.181
(-0.42)
C21H24N6O5
RDB = 13
(E)-N2-isobutyryl-8-[2-(pyrid-4-yl)-ethenyl]-2’-
deoxyguanosine��� (1)
22 0.223 inactive
end
440.180
(2.53)
C20H28N2O9
RDB = 8
Nα-(benzyloxycar bonyl)-Nδ-(β-D-fucopyranosyl)-L
-glutamine O-methyl ester��� (2)
N_14968 5.97 204.071 205.079 no prediction no hits 13 0.255 0.099
P_11822 8.19 322.081 321.075
(-2.53)
C17H11N3O4
RDB = 14
N”-(5-hydroxy-2-oxoindolin-3-ylidene)benzofuran-2-
carbohydrazide��� (3)
13 0.193 0.080
P_11803� 10.66 379.165 378.158
(-0.98)
C22H22N2O4
RDB = 13
2-[3-hydroxy-2-methoxy-1-(1H-indol-3-yl) propyl]-
1H-indole-3-acetic acid�� (4C)/marine-derived
Rubrobacter radiotolerans
13 0.078 0.048
N_4053 11.35 566.245 567.252
(-0.008)
C37H33N3O3
RDB = 23
2,3,6-triphenyl-1-phenylcarbamoyl-4-phenylcarbamoyl
hydroxypiperidine��� (5)
22 0.082 inactive
end
N_2018 11.83 566.245 567.252
(-0.008)
C37H33N3O3
RDB = 23
22 0.087 0.079
P_11816 11.85 590.226 589.221
(-3.03)
C35H31N3O6
RDB = 22
4-amino-6,10-diaroyl-7,9-diaryl-8-oxa-2,3-diazaspiro
[4,5]deca-3-en-1-ones��� (6)
22 0.115 0.064
N_2020 12.61 305.138 306.144
(3.18)
C13H18N6O3
RDB = 8
N’,N”-[(2-oxo-1H-benzimidazole-1,3(2H) -diyl)bis
(methylene)] diacetohydrazide��� (7)
6 deleted
inactive outlier
0.070
P_11819 12.68 379.165 378.158
(-0.98)
C22H22N2O4
RDB = 13
nocazine A�� (4A) /
marine-derived
Nocardiopsis dassonvillei HR10-5
13 0.078 0.081
2’-deoxy clavulanic acid��(4B) /
Streptomyces clavuligerus
N_2019 12.85 566.245 567.252
(-0.35)
C37H33N3O3
RDB = 23
2,3,6-triphenyl-1-phenylcarbamoyl-4-phenylcarbamoyl
hydroxypiperidine��� (5)
22 0.082 0.066
P_17236 12.87 568.244 567.237
(0.08)
C33H33N3O6
RDB = 19
3’,6’-dimethoxy-N-(4’-((1-methyl piperidin-4-yl)oxy)-
3’-nitro-[1,1’-biphenyl]-4-yl-[1,1’-biphenyl]-
3-caboxamide��� (8)
22 0.230 0.197
P_15328� 14.66 330.181 329.174
(-1.17)
C18H23N3O3
RDB = 9
3-(2-(amino) acetamido)benzofuran-2-carboxamide���
(9)
13 0.217 inactive
end
P_15267� 15.16 312.170 311.163
(-0.03)
C18H21N3O2
RDB = 10
talathermophilin E (10) / Talaromyces thermophilus
YM3-4
13 0.211 inactive
end
�major peaks found on the base peak chromatogram as presented in S2 Table and S3 Table
��interchangeable
���Chemspider hits from reported antimicrobial synthesized compounds
https://doi.org/10.1371/journal.pone.0226959.t002
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exhibited chemical shifts between 3 and 10 ppm for the active end while the inactive end was
dominated by aliphatic signals ranging from 0 to 2 ppm.
OPLS-DA plots (Fig 6E and 6F) for the bioactivity of the isolates on E. coli suggested MS.
REE. 3, 6, 14, and 22 as the most distinct in terms of their chemical profile as shown by the
scores plot on Fig 6E. However, the S plot on Fig 6F did not indicate a clear separation of the
type of chemical shifts between the active and inactive group, although a higher density of the
aromatic signals (6–8 ppm) can be observed on the active end. This was also indicated by the
overlapping of the active and inactive isolates on the scores plot resulting to a small difference
in variation scores within and between groups at 18.7% and 14.8%, respectively.
Dereplication of the selected isolates
As mentioned above, two outlying isolates MS.REE. 13 and 22 were found highly active against
all bacterial strains tested. Isolates MS.REE. 13 and 22 were then revisited and investigated
intensively in terms of their dereplication results. Both isolates yielded a high number of m/z
features for their respective extracts (S1 Table). The total number of features combined from
both positive and negative ionization mode for MS.REE. 13 was 8885, which was a little bit
more than MS.REE. 22, which had 8831 features. About 48% of the features detected in MS.
REE. 13 were known metabolites while 52% afforded no matching hits from the DNP database.
This result was very similar to MS.REE. 22, which had 47% of its features as known com-
pounds while the remaining 53% had no hits in the DNP database (S1 Table). This dereplica-
tion result indicated a higher occurrence of novel metabolites from both selected isolates as
more than 50% of their metabolites afforded no matching hits from the DNP database. Table 2
summarizes the dereplication of the interesting metabolites indicated on the active side of the
S-plot for the anti-MRSA and anti-E. coli activities with highest peak intensities occurring
either MS.REE. 13 or MS.REE. 22. Most of the m/z features in Table 2 were unidentified from
the DNP database, which are promising for novel natural products discovery. Compounds
with matching hits from the DNP database listed in Table 2 were putatively identified as earlier
reported from microbial natural products.
Regarding isolate MS.REE. 13, as shown in S2 Table, all the predicted molecular formula of
the major ion peaks exhibited a high number of oxygen atoms or the presence of both oxygen
and nitrogen moieties, which indicated the occurrence of either glycosidic compounds or pep-
tides. This matched the result of NMR loadings plot where isolate MS.REE. 13 afforded higher
density of chemical shifts in the 3 to 5 ppm region indicated by the yellow dots as shown on
Fig 5. Column plots of the relative abundance of predicted bioactive metabolites against MRSA. (5A) and E. coli (5B) unique to isolates
MS.REE. 13, 22, 3, and 6, respectively. The predicted bioactive metabolites are listed under their MZmine IDs in Table 2.
https://doi.org/10.1371/journal.pone.0226959.g005
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the left upper quadrant of the loadings plot in Fig 6B. This can be confirmed from the COSY
correlation spectrum of MS.REE. 13 that when overlaid with that of the culture medium, it
indicated peaks at 3 to 5 ppm exclusively from isolate 13 (S2 Fig). Dereplication study showed
that most of the higher intensity ion peaks of MS.REE. 13 (S3A and S3B Fig) yielded hits from
the DNP database (S2 Table). However, some of the matching hits of the identified metabolites
were of fungal origin and not from actinomycetes while only two hits were putatively identi-
fied as bacterial metabolites. Most of the higher intensity ion peaks from isolate MS.REE. 13
were also indicated on the bioactive end of the S-plot. The dereplication of the classified bioac-
tive compounds afforded some interesting hits that included ion peak at m/z 379.165 [M+H]+,
with a predicted molecular formula of C22H22N2O4. which was putatively identified as bacterial
Fig 6. Multivariate analysis of the 1H-NMR chemical shift data in ppm of 25 extracts tested against MRSA and E. coli. (6A) PCA-scores
and (6B) -loadings plot of 25 isolates. OPLS-DA scores plot against MRSA (6C) and E. coli (6E). OPLS-DA loadings S-plot of isolates against
MRSA (6D) and E. coli (6F).
https://doi.org/10.1371/journal.pone.0226959.g006
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metabolites 4A, B, or C. This ion peak was putatively identified as either nocazine A (4A), a
metabolite isolated from the marine actinomycete Nocardiopsis dassonvillei HR10-5 [66]. This
feature was also putatively identified as 2’-deoxy,2’-dibenzylamino clavulanic acid (4B), a
derivative of clavulanic acid which was first described to be produced by Streptomyces clavuli-
gerus (S. clavuligerus) ATCC 27064 as a β-lactamase inhibitor [67] or (2-[3-hydroxy-2-meth-
oxy-1-(1H-indol-3-yl)propyl]-1H-indole-3-acetic acid) (4C), an actinobacterial metabolite
isolated from marine-derived actinomycete Rubrobacter radiotolerans [68] (Fig 7). The MS
fragmentation of the ion peak at m/z 379.165 [M+H]+ with a retention time of 10.66 min,
which was among the major peaks observed from the base peak chromatogram of MS.REE. 13
(S6 Fig) was compatible to that of 4C. Another ion peak at m/z 312.170 [M+H]+ with a pre-
dicted formula of C18H21N3O2 was putatively identified as the fungal metabolite talathermo-
philin E (10), which was isolated from fungus Talaromyces thermophilus strain YM3-4 [69]
(Fig 7).
Through inspection of the HRMS chromatogram of MS.REE. 22, which was overlaid with
the chromatogram of the culture medium, it was observed that many of the major ion peaks
did belong to MS.REE. 22 in both positive and negative ionization modes (S4A and S4B Fig).
Listed ion peaks shown in S3 Table were mostly higher intensity peaks that did not yield any
hits from the DNP database, which is quite promising to go for further scale-up chemical isola-
tion work. It was also interesting to note that the RDBs of the predicted molecular formula of
most of the higher intensity peaks observed in MS.REE. 22 were between 5 and 13 ppm indi-
cating the presence of aromatic and/or olefinic compounds. The presence of the aromatic and/
or olefinic compounds was also demonstrated by the results shown in Fig 6D. Target bioactive
features for isolate MS.REE. 22 on the NMR loadings plot (Fig 6D) exhibited chemical shifts at
5–7 ppm and were also highlighted in the COSY correlation spectrum as shown in S5 Fig. As
found in isolate MS.REE. 13, isolate 22 afforded a similar major ion peak at m/z 379.165 [M
+H]+.
Other ion peaks that were detected on the active end of the S-plots but were not matched to
any compounds from the DNP included ion peaks at m/z [M+H]+ 312.170, 322.081, 330.181,
379.165, 441.181, 568.244, and 590.226, while for the negative mode, ion peaks at m/z [M-H]-
204.071, 305.138, and 566.245 were found. Except for the ion peak at m/z 204.071 [M-H]-, all
ion peaks generated a predicted molecular formula and the putatively identified bioactive
metabolites contained both nitrogen and oxygen with RDBEs between 8 to 23. Using Chem-
spider, the predicted molecular formulas with the search term “antimicrobials”, synthetically
produced compounds were dereplicated, which included 8-substituted-2’-deoxyguanosines
(1) [70], glycosyl amides (2) [71], benzofurans (3, 9) [72, 73], diphenyl-4-hydroxypiperidines
(5) [74], spiro heterocycles (6) [75], benzimidazoles (7) [76] and biphenyls (8) [77]. N_2020 or
compound 7 was dereplicated as an antimicrobial synthetic benzimidazole congener [76] and
was a metabolite determined to be putatively specific against E. coli. Synthesized benzimid-
azoles have been lately described for their antibacterial activities similarly against S. aureus and
E. coli [78].
The dereplication work done in this study, was used to assist the isolation of the bioactive
metabolites from the selected isolates. From the 12 putatively dereplicated targeted bioactive
compounds listed on Table 2 in this study, only four were natural products (4A, 4B, 4C, and
10) that were previously described from Actinomycetes, while solely metabolite 4B (2’-deoxy
clavulanic acid) was the only one reported to be isolated from a Streptomyces species. All these
putatively identified known natural products were dereplicated from both MS.REE. 13 and 22,
with higher concentrations found in MS.REE. 13. S2 Table and S3 Table listed the 6 major
peaks for each isolates including those two ion peaks identified to be the bioactive metabolites
4A, 4B or 4C, and 10. However, the other two ion peaks dereplicated for isolate 13 were
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described as fungal metabolites while two other peaks did not give any matching hit. For iso-
late 22, the rest of the major ion peaks did not find any matching hit from the DNP database.
This dereplication step indicated the uniqueness of the chemical profiles of MS.REE. 13 and 22
with novel natural products to be subjected for further chromatographic isolation work. How-
ever, it was also important and necessary to explore the type of bioactive compounds that will
Fig 7. Chemical structures of dereplicated bioactive metabolites for the selected isolates MS.REE. 3, 6, 13 and 22.
https://doi.org/10.1371/journal.pone.0226959.g007
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match the predicted molecular formula from a database like Chemspider. The set of informa-
tion provided by the dereplication study, specifically those hits found from Chemspider albeit
chemically synthesized compounds was still a useful aid in determining the mode of isolation
work and structural elucidation tools needed to identify the bioactive metabolites. The
deduced information from Chemspider on the type of the expected chemistry for these new
bioactive natural products were compatible with the NMR spectral data as already mentioned
above and as shown in S2 Fig as well as indicated by the NMR loadings plot (Fig 6D and 6F)
for focusing into the functional groups responsible for the bioactivity of the predicted metabo-
lites. The dereplication work presented here will not be conclusive in terms of elucidating the
structure of the compounds but the objective of this study is to put together a systematic meth-
odology that would be statistically robust in prioritizing isolates from an underexplored collec-
tion of microorganisms for further tedious chemical work in finally identifying the
antibacterial compound. The results of this dereplication study coupled to a metabolomics
approach by utilizing multivariate analysis has provided the practicality of targeting and pin-
pointing the bioactive metabolites as also shown by our earlier studies [17, 22, 29–37]. Such a
coupled approach has proven to be time and cost-efficient when the target bioactive metabo-
lites were directly pinpointed and partially elucidated from the first fractionation stage.
The utilization of MVA was shown to identify the bioactive metabolite regardless of its con-
centration in the fraction of the crude extract by using the OPLS-DA loadings S-plot. The
metabolites were distributed according to the same quadrants to where the active and inactive
fractions were positioned on the OPLS-DA scores plots. This approach rectified the common
oversight in a bioassay-guided isolation procedure where the major components of a bioactive
crude extract or fraction were more perceptibly targeted to afford a pure but inactive metabo-
lite. In this study, it was demonstrated that the major ion peaks detected on the base peak chro-
matogram (S3A and S3B Fig, and S4A and S4B Fig) were not designated as the bioactive
metabolite in the OPLS_DA loadings S-plot. The ion peaks were not detectable in the base
peak chromatogram either due to their low yield or poor ionization capability. It is, indeed,
however a challenge when a metabolomics-guided approach is utilized to target a bioactive
metabolite that is present in a crude extract or fraction at nanogram levels, which could be
unfeasible to isolate. In addition, the relative concentration of the ion peaks on the total ion
chromatogram is highly dependent on the ability of the respective compounds to ionize at cer-
tain modes and methods of ionization, for this reason, the NMR spectral data does support the
analysis for the “true” relative abundance of the various metabolites. The isolated compounds
afforded medium to weaker antibiotic activity with MICs from 250 to 800 μM. Albeit, the
occurrence of these isolated compounds was apparent only on the active quadrant of the
OPLS-DA loadings plot of the crude extracts (Fig 8A–8C) and not found in the inactive side of
the plot. Two new compounds, P_24306 (C10H13N2) and N_12799 (C18H32O3) with MICs of
795 and 432 μM, were afforded from the scale-up of MS.REE. 13 and 22, respectively (Fig 8B
and 8C). Fractionation of the scaled-up isolates MS.REE. 13 and 22 did reveal the targeted bio-
active metabolites listed on Table 2 along with the isolated compounds on the active quadrant
of the OPLS-DA plot grouped according to their activity against MRSA. It was also demon-
strated that the isolated compounds were not easily ionized in the electro-spray ionization
mass spectral platform resulting to the low intensity of their mass ion peaks although the corre-
sponding proton signals can be detected by NMR (Fig 6D) with resonances between 0–3 ppm
for the acetylated aliphatic alkyl chain and 4–6 ppm for the hydroxylated and olefinic moieties.
The mass ion peak intensities of the isolated compounds did improve preceding fractionation.
A bioassay- and metabolomic-guided approach was also used to chromatographically isolate
the bioactive metabolites shown on Fig 8D and 8E. Subsequent to fractionation, the detected
bioactive metabolites from the crude extracts were still positioned on the active quadrant.
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However, it was also observed that a new set of bioactive metabolites were also detected. As the
concentration of the less ionized bioactive metabolites increased, it was feasible to go over its
threshold level for quantification.
Molecular biological characterization of the selected actinomycete isolates
The amplified 16S rRNA gene sequences of the selected isolates MS.REE. 13 and 22 showed
very high similarity (100% and 99% respectively) with many Streptomyces sp. sequences in
NCBI GenBank. The partial 16S rRNA gene sequences of MS.REE. 13 and 22 aligned with closely
Fig 8. Mapping the targeted and isolated bioactive metabolites on OPLS-DA plots. (8A) OPLS-DA loadings plot of crude extracts. The isolated compounds are
represented by a 4-point star. (8B) Dereplication table and bioassay results against MRSA for the isolated compounds with streptomycin as positive standard. (8C)
Structures of the isolated bioactive compounds. (8D) OPLS-DA loadings plot of MS. REE. 13 fractions. (8E) OPLS-DA loadings plot of MS. REE. 22 fractions. Both
isolated and the targeted bioactive metabolites were marked with a 4-point star.
https://doi.org/10.1371/journal.pone.0226959.g008
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related sequences from the NCBI GenBank and by using MEGA7 software, the phylogenetic tree
of the isolates was created using the Neighbor-Joining method. As shown in Fig 9, many Strepto-
myces hits were similar to our selected isolates which confirmed that they belong to the genus
Streptomyces. However, it was difficult to assign the taxonomical classification to the species
level. Therefore, both isolates were classified as Streptomyces sp., which is consistent with an ear-
lier report [79] mentioning that 16s rRNA gene sequencing is an insufficient tool to assign the
phylogeny of the closely related species because of the conserved sequences. The results of the
present study partially matches earlier studies [80] as they managed to define the phylogenetic
identification of many Streptomyces sp. using the 16S rRNA sequencing of many strains, however
it was not a useful tool to identify some other strains to species level in the same study.
The closely related actinomycete S. rochei have the biggest number of 37 reported natural
products with 15 compounds described to exhibit antimicrobial activity (antibacterial or anti-
fungal). Interesting metabolites were detected in the selected isolates MS.REE. 13 and 22 that
were earlier isolated from S. rochei which was the only related species producing these derepli-
cated metabolites, while the other species neighbor to our selected isolates did not afford any
matching compounds in the dereplication study. Five putatively identified metabolites were
earlier described from S. rochei, from which four compounds were detected from MS.REE. 22
and three metabolites were found in MS.REE. 13 with two shared compounds produced by
both isolates (Table 3, Fig 10). One of the interesting hits was the ion peak at m/z 418.259 [M
+H]+ that was yielded from MS.REE. 13, with a molecular formula of C24H35NO5, which was
putatively identified as lankacyclinol (11). Lankacyclinol (11) or also known as antibiotic T
2636G is a polyene-type antibiotic that exhibited potent antimicrobial activity [84, 85]. Fur-
thermore, another ion peak at m/z 490.316 [M+H]+ with predicted molecular formula of
C28H43NO6 that was detected in both isolates MS.REE. 13 and 22 was putatively identified as
borrelidin (12), an antiviral agent also isolated from S. rochei [86, 87]. The MS fragmentation
of the ion peak at m/z 490.316 [M+H]+ is shown on S7 Fig that is compatible for borrelidin
(12). On the other hand, another derivative with a molecular formula of C26H37NO6 was
found at m/z 460.270 [M+H]+, which was only produced by MS.REE. 22 was putatively identi-
fied as lankacyclinol A (13) also named as antibiotic T 2636E [85]. Another ion peak detected
in MS.REE. 22 was found at m/z 801.501 [M+H]+ with a molecular formula of C42H72O14 and
was identified to be 8,15-dideoxylankamycin (14), a compound isolated from a mutant strain
of S. rochei [88]. This metabolite was a derivative of the macrolide antibiotic lankamycin [88,
89]. The MS fragmentation of the ion peak at m/z 801.501 [M+H]+ is presented on S8 Fig that
is well-matched for 8,15-dideoxylankamycin (14). Due to the observed lower intensity ion
peaks at m/z [M+H]+ 418.259 and 460.270, it was not plausible to deduce any MS fragmenta-
tion data. These dereplication results were essential to further confirm chemotaxonomical
relationship of the bioactive isolates found in this current collection to the strain S. rochei.
Although chemical biomarkers specific for S. rochei were found and dereplicated, these com-
pounds were not necessarily responsible for the bioactivity of the crude extracts as indicated in
this study. For this two-year research project, due to time and funding constraints, it was only
possible to subject two isolates for taxonomical identification and hence, it was vital to set-up
this metabolomics-guided dereplication approach in prioritizing the isolates for further work.
Taxonomical work would entail full data analysis for the biochemical identification, morpho-
logical characterization, 16S rRNA and DNA-DNA hyperdization.
Conclusions
A total of 58 isolates were isolated from different soil samples collected from Ihnasia City,
Egypt from which 25 isolates were active against at least one of the tested indicator microbial
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strains. Chemical profiles of the bioactive crude extracts were investigated using both NMR
and LC-HRMS followed by multivariate analysis which was performed for 25 bioactive
Fig 9. Phylogenetic tree of MS.REE. 13 and MS.REE. 22 isolates based on partial 16S rRNA gene sequences. The phylogenetic tree was inferred using the Neighbor-
Joining method [81]. The distances were computed using the Kimura 2-parameter method [82] and are in the units of the number of base substitutions per site.
Numbers at nodes indicate percentages of 1000 bootstrap re-samplings. The analysis involved 25 nucleotide sequence. Codon positions included were 1st+2nd+3rd
+Noncoding. All positions containing gaps and missing data were eliminated. Evolutionary analyses were conducted in MEGA7 [83].
https://doi.org/10.1371/journal.pone.0226959.g009
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extracts. PCA was used to differentiate the isolates depending on their chemical diversity and
novelty, while OPLS-DA was used to compare the chemical profiles of the NMR and mass
spectral data of the isolates by classifying the extracts and fractions according to their biological
activity. The tested isolates exhibited a chemical diversity of 84% indicating four outlying
extracts MS.REE. 3, 6, 12, and 22 by PCA. MS.REE.13 and 22 were chosen for scale-up work.
On the other hand, outliers MS.REE. 3 and 6, which were only found active against E. coli and
inactive against MRSA that was the main target activity for initial scale-up work, were then
excluded for further analysis. Dereplication with a metabolomics approach was a fascinating
tool used for isolate selection and prioritization as it helped in predicting the probability of
each isolate to produce novel compounds, the functional groups responsible for the bioactivity,
and to know the source of each metabolite which was preliminarily identified putatively. By
correlating the dereplication results with the biological activity of the isolates, it was demon-
strated that selection of isolates which were both biologically active and had interesting chemi-
cal profiles could support the efforts of the drug discovery campaign and increases the chance
for the discovery of novel natural products. The metabolomics approach was a valuable tool in
isolate prioritization for drug discovery programs due to the low chance of redundancy of iso-
lating the same set of compounds with similar reported bioactivities. A metabolomics-guided
approach provided the lead to targeting bioactive metabolites that are present in a crude
extract or fraction even at nanogram levels, which may not be perceivable in a chromatogram,
but it is, however, a challenge that such low yields would be feasible to isolate. The isolated
compounds exhibited medium to weak antibiotic activity with MICs from 250 to 800 μM
while their occurrence was established to be only on the active side of OPLS-DA loadings plot
(Fig 8). Two new compounds, P_24306 (C10H13N2) and N_12799 (C18H32O3) with MICs of
795 and 432 μM, were afforded from the scale-up of MS.REE. 13 and 22, respectively. Most
active were (E)-14-methylpentadec-9-enoic acid and 15-methylhexadecanoic acid with MIC
values of approximately 250 μM due to their enhanced capability to permeate the lipophilic
cell membrane [90]. The pinpointed bioactive natural products (P<0.01) through a metabolo-
mics approach, particularly those established by mass spectrometry, will have to be revisited to
enhance their production and yield, which would need optimization of the culture media by
changing the carbon or nitrogen sources or the addition of elicitors.
However, as realized in this study, it is important to use a combination of analytical tools to
target all types of diverse chemistry. Such analytical tools must also include a combination of
different ionization platforms for mass spectrometry albeit NMR spectroscopy does fill up the
gap in getting the entire representation of the different ratios of the various compounds pres-
ent in a mixture, the presence of metabolites at micro- or nanogram levels is not feasible to
Table 3. Dereplicated metabolites, which were earlier reported from related species S. rochei as detected in the phylogenetic analysis of the bioactive isolates MS.
REE. 13 and 22. Structures of compounds 11 to 14 are shown in Fig 10.
MZmine ID RT m/z MW
(accuracy in ppm)
Predicted Molecular formula Putative compound identified Isolate yielding the metabolite
N_ 2571 16.20 656.270
[M-H]-
657.278
(-0.64)
C34H43NO12 antibiotic T 2636K 13
22
P_ 22661 18.58 418.259
[M+H]+
417.251
(-1.15)
C24H35NO5 lankacyclinol (11) 13
P_ 7908 19.03 490.316
[M+H]+
489.309
(0.007)
C28H43NO6 borrelidin (12) 13
22
P_32128 21.29 460.27
[M+H]+
459.262
(1.35)
C26H37NO6 lankacyclinol A (13) 22
P_ 33188 23.42 801.501
[M+H]+
800.492
(2.09)
C42H72O14 8,15-dideoxylankamycin (14) 22
https://doi.org/10.1371/journal.pone.0226959.t003
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detect. From this study, it was further concluded that Egyptian soil actinomycetes samples
were found to be still a rich source of biologically active natural products worth for further
research.
Supporting information
S1 Fig. Antimicrobial activity screening of crude extracts using cup diffusion method
against B. subtilis as illustrated for MS.REE. 1, 3, 4, and 6. The zones of inhibition were mea-
sured and recorded as active when it was greater than 12 mm. Twenty-five bioactive isolates
were found out of the total of 58 isolated actinomycetes.
(DOCX)
Fig 10. Chemical structures of dereplicated metabolites earlier reported from related species S. rochei.
https://doi.org/10.1371/journal.pone.0226959.g010
Screening of bioactive natural products from soil actinomycetes
PLOS ONE | https://doi.org/10.1371/journal.pone.0226959 December 30, 2019 23 / 29
S2 Fig. 2D-NMR COSY spectrum of MS.REE. 13 overlaid with culture medium. Signals in
orange are from the MS.REE. 13 and signals in grey are from the culture medium. Highlighted
correlations indicate the significant chemical shifts which made MS.REE. 13 an outlier.
(DOCX)
S3 Fig. Base peak chromatograms of both positive and negative modes for the bacterial
extract of MS.REE. 13, annotated to indicate major metabolites produced by the bacteria
and are not from the medium shown in S2 Table. (A) Positive ion mode and (B) Negative
ion mode.
(DOCX)
S4 Fig. Base peak chromatograms of both positive and negative modes for the bacterial
extract of MS.REE. 22, annotated to indicate major metabolites produced by the bacteria
and are not from the medium shown in S3 Table. (A) Positive ion mode and (B) Negative
ion mode.
(DOCX)
S5 Fig. 2D-NMR COSY spectrum of MS.REE. 22 overlaid with culture medium. Signals in
orange are from the MS.REE. 22 and signals in grey are from the culture medium. Highlighted
correlations indicate the significant chemical shifts which made MS.REE. 22 an outlier.
(DOCX)
S6 Fig. HRMS fragmentation of the ion peak at m/z 379.165 [M+H]+ for 2-[3-hydroxy-
2-methoxy-1-(1H-indol-3-yl) propyl]-1H-indole-3-acetic acid (4C).
(DOCX)
S7 Fig. HRMS fragmentation of the ion peak at m/z 490.316 [M+H]+ for borrelidin (12).
(DOCX)
S8 Fig. HRMS fragmentation of the ion peak at m/z 801.501 [M+H]+ for 8,15-dideoxylan-
kamycin (14).
(DOCX)
S1 Table. Summary of the total number of features (m/z) detected in the bioactive outlying
bacterial extracts (MS.REE. 13 and 22) including number of features in negative and positive
modes after solvent peaks removal (a), number of features after removing the effect of the cul-
ture medium (b) and number of both unknown and putatively identified features from DNP
database (c).
(DOCX)
S2 Table. Dereplication of selected major ion peaks in MS.REE. 13.
(DOCX)
S3 Table. Dereplicated selected major ion peaks in MS.REE. 22.
(DOCX)
S4 Table. Different seasons during which the bioactive isolates were collected.
(DOCX)
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